Organotypic models of patient-specific tumours are revolutionizing our understanding of
cancer heterogeneity and its implications for personalized medicine. These advancements …

Therapy resistance is a major problem when treating cancer patients as cancer cells
develop mechanisms that counteract the effect of therapeutic compounds, leading to fit and …

Background & Aims Tumor-microenvironment factors and cancer stem cells (CSCs) play a
critical role in the aggressiveness of pancreatic cancer (PC). However, the degree to which …

Oxaliplatin is the first-line regime for advanced gastric cancer treatment, while its resistance
is a major problem that leads to the failure of clinical treatments. Tumor cell heterogeneity …

Pancreatic ductal adenocarcinoma (PDAC) shows pronounced epithelial and mesenchymal
cancer cell populations,,–. Cellular heterogeneity in PDAC is an important feature in disease …

There is increasing evidence that malignant tumors are initiated and maintained by a sub-
population of tumor cells that have similar biological properties to normal adult stem cells …

Phagocytosis is required for the optimal efficacy of many approved and promising
therapeutic antibodies for various malignancies. However, the factors that determine the …

Intratumour heterogeneity (ITH) has become an important focus of cancer research in recent
years. ITH describes the cellular variation that enables tumour evolution, including tumour …

Cancer cells rely on certain extracellular nutrients to sustain their metabolism and growth.
Solute carrier (SLC) transporters enable cells to acquire extracellular nutrients or shuttle …

Cancer stem-like cells (CSCs) contribute to cancer metastasis, drug resistance and tumor
relapse, yet how amino acid metabolism promotes CSC maintenance remains exclusive …